Abstracts Archive - Page 901 of 2425 - ACR Meeting Abstracts

Abstract Number: 2140 • 2019 ACR/ARP Annual Meeting
Preexisting Autoimmune Disease and Rheumatic Immune-Related Adverse Events Associated with Cancer Immunotherapy: A Case Series from the Canadian Research Group of Rheumatology in Immuno-Oncology (CanRIO)
Linda Laaouad¹, Janet Roberts ², Daniel Ennis ³, Carrie Ye ⁴, Karam Al Jumaily ⁵, Marie Hudson ⁶, Shahin Jamal ⁷, Janet Pope ⁸, Tatiana Nevskaya ⁹, Alexandra Saltman ¹⁰, Megan Himmel ¹¹, Aurore Fifi-Mah ¹², Annaliese Tisseverasinghe ¹³, Nancy Maltez ¹⁴, Ines Colmegna ¹⁵ and Sabrina Hoa ¹⁶, ¹University of Montreal, Montreal, Canada, ²Dalhousie University, Halifax, Canada, ³University of Toronto, Toronto, ON, Canada, ⁴University of Alberta, Edmonton, AB, Canada, ⁵University of Alberta, Edmonton, Canada, ⁶Jewish General Hospital, Lady Davis Institute for Medical Research, and Department of Medicine, McGill University, Montreal, QC, Canada, ⁷University of British Columbia, Vancouver, BC, Canada, ⁸Western University, London, ON, Canada, ⁹University of Western Ontario, London, ON, Canada, ¹⁰University of Toronto, Mount Sinai Hospital and Princess Margaret Cancer Centre, Toronto, ON, Canada, ¹¹University of Toronto, Toronto, Canada, ¹²University of Calgary, Calgary, AB, Canada, ¹³University of Manitoba, Winnipeg, MB, Canada, ¹⁴University of Ottawa, Ottawa, ON, Canada, ¹⁵McGill University Health Center, Montreal, QC, Canada, ¹⁶University of Montreal, Montreal, QC, Canada
Background/Purpose: Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy by harnessing the immune system to fight cancer, but are associated with significant immune-related adverse events…
Abstract Number: 2141 • 2019 ACR/ARP Annual Meeting
Rituximab Therapy for Interstitial Pneumonia with Autoimmune Features (IPAF): A Case Series of Nineteen Patients
Kristin D'Silva¹, Marcy Bolster ¹, Flavia Castelino ², Amita Sharma ¹, Brent Little ¹, Sydney Montesi ¹ and Hyon K. Choi ¹, ¹Massachusetts General Hospital, Boston, MA, ²Harvard University, Boston, MA
Background/Purpose: Interstitial lung disease (ILD) is a major cause of morbidity and mortality in patients with connective tissue diseases (CTD). Approximately one-third of patients with…
Abstract Number: 2142 • 2019 ACR/ARP Annual Meeting
Frailty in Systemic Rheumatic Diseases: A Systematic Review
Sarah Lieber¹, Abigail Schmucker ² and Lisa Mandl ³, ¹Hospital for Special Surgery, New York, ²Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA, ³Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, New York, NY
Background/Purpose: Frailty, a state of decreased homeostatic reserve, is well studied in the elderly and is independently associated with increased morbidity and mortality. Many systemic…
Abstract Number: 2143 • 2019 ACR/ARP Annual Meeting
Neuromyelitis Optica Overlaps Frequently with Systemic Rheumatic Diseases in African-Americans: Experience at a Large US Academic Medical Center
Michael Belsky¹, Sunita Dia ², Hassan Amer ², Christopher Collins ¹ and Konstantinos Loupasakis ¹, ¹MedStar Washington Hospital Center, Department of Rheumatology, Washington, DC, ²MedStar Washington Hospital Center, Department of Internal Medicine, Washington, DC
Background/Purpose: Neuromyelitis optica (NMO) and neuromyelitis optica spectrum disorders (NMOSD) are immune-mediated demyelinating disorders of the central nervous system, primarily characterized by optic neuritis and…
Abstract Number: 2144 • 2019 ACR/ARP Annual Meeting
Musculoskeletal Immune-Related Adverse Events After Immune Checkpoint Inhibitor Therapy: Single Center Experience
Didem Saygin¹, Melissa Bastacky ¹, Gerard Mascara ¹, Timothy L Brenner ¹, Chester Oddis ¹, Siamak Moghadam-Kia ¹, Dana Ascherman ¹, Diwakar Davar ¹ and Rohit Aggarwal ¹, ¹University of Pittsburgh Medical Center, Pittsburgh, PA
Background/Purpose: Immune checkpoint inhibitors (ICI) are new anti-cancer agents used for lung cancer, melanoma, renal cell and urothelial carcinoma, and head and neck cancers. They…
Abstract Number: 2145 • 2019 ACR/ARP Annual Meeting
Long-term Safety of Tildrakizumab in Patients with Moderate-to-Severe Plaque Psoriasis: Incidence of Severe Infections Through 3 Years (148 Weeks) from 2 Phase 3 Trials
Diamant Thaçi ¹, Kristian Reich ², Jo Lydie Lambert ³, Lars Iversen ⁴, Andrea Peserico ⁵, Ignasi Pau-Charles ⁶, Andrew Blauvelt⁷ and Christopher Griffiths ⁸, ¹Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany, Lübeck, Germany, ²University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Skinflammation®, Hamburg, Germany; Dermatologikum Berlin, Berlin, Germany, Hamburg, Germany, ³Department of Dermatology, Ghent University Hospital, Ghent, Belgium, Ghent, Belgium, ⁴Department of Dermatology, Aarhus University Hospital, Aarhus, Denmark, Aarhus, Denmark, ⁵Clinica Dermatologica, Department of Medicine-DIMED University of Padua, Padua, Italy, Padua, Italy, ⁶Almirall R&D, Barcelona, Spain, Barcelona, Spain, ⁷Oregon Medical Research Center, Portland, OR, USA, Portland, OR, ⁸Centre for Dermatology Research, The University of Manchester, Manchester, UK, Manchester, United Kingdom
Background/Purpose: Tildrakizumab (TIL) is a high-affinity anti–interleukin-23p19 monoclonal antibody approved for the treatment of moderate-to-severe plaque psoriasis. The objective of this study was to evaluate…
Abstract Number: 2146 • 2019 ACR/ARP Annual Meeting
Complications of Immune Checkpoint Inhibitor Therapy in Patients with and Without Pre-existing Rheumatologic Disease
Emily Carroll¹, Amanda Leiter ², Danielle Brooks ¹, Jennifer Ben Shimol ³, Elliot Eisenberg ¹, Matthew Galsky ⁴, Emily Gallagher ⁵ and Margrit Wiesendanger ³, ¹Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, ²Division of Endocrinology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, ³Division of Rheumatology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, ⁴Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, ⁵Division of Endocrinology, Department of Medicine, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York
Background/Purpose: Immune checkpoint inhibitors (ICIs) are effective therapies in the treatment of many cancers, but their use has been linked with immune-related adverse events (irAEs).…
Abstract Number: 2147 • 2019 ACR/ARP Annual Meeting
Musculoskeletal Ultrasound Enhances the Evaluation of Checkpoint Inhibitor Associated Musculoskeletal Immune Related Adverse Events
Mazen Nasrallah¹, Sara Schoenfeld ², Mark Matza ¹, Donald Lawrence ², Justine Cohen ², Meghan Mooradian ², Kerry Reynolds ², Ryan Sullivan ² and Minna Kohler ², ¹Massachusetts General Hospital, Boston, ²MGH, Boston
Background/Purpose: Cancer immunotherapy with monoclonal antibodies that antagonize molecular checkpoint pathways in immune activation, the PD-1/PDL1 axis and CTLA-4, have revolutionized the treatment of solid…
Abstract Number: 2148 • 2019 ACR/ARP Annual Meeting
Muscle Involvement Revealed by 18F-PET-CT in Polymyalgia Rheumatica
Daniel WENDLING¹, Maxime SONDAG ², Nicolas GIRAUD ², Mickael CHOUK ², Hatem Boulahdour ², Clément PRATI ² and Frank VERHOEVEN ³, ¹Rheumatology, University Teaching Hospital (CHRU), Besançon, France, ²University Teaching Hospital (CHRU), Besançon, France, ³CHU Besancon, BESANCON, France
Background/Purpose: Imaging techniques in polymyalgia rheumatica (PMR) have revealed mainly bursitis, tenosynovitis, capsulitis and enthesitis. This is also the case for 18F-FDG-PET-CT. This technique, which…
Abstract Number: 2149 • 2019 ACR/ARP Annual Meeting
Principal Components Analysis as a Tool to Identify Lesional Skin Patterns in Cutaneous Lupus Erythematosus
Smriti Prasad¹, Justin Raman ¹, Motolani Ogunsanya ² and Benjamin Chong ³, ¹University of Texas Southwestern Medical Center, Dallas, ²OU College of Pharmacy, Oklahoma City, ³University of Texas Southwestern, Dallas
Background/Purpose: Cutaneous lupus erythematosus (CLE) has multiple subtypes that account for a broad range of presentations. The preferential locations of skin lesions have only been…
Abstract Number: 2150 • 2019 ACR/ARP Annual Meeting
Frequency of Polyautoimmunity in a Tertiary Hospital
Elena Grau García¹, José Ivorra Cortés ¹, Jorge Juan Fragio Gil ¹, Roxana Gonzalez Mazarío ¹, Marta de la Rubia Navarro ¹, Cristóbal Pavez Perales ¹, Cristina Alcañiz Escandell ¹, Inmaculada Chalmeta Verdejo ¹, Luis González Puig ¹, Isabel Martínez Cordellat ¹, Rosa Negueroles Albuixech ¹, José Eloy Oller Rodríguez ², Francisco Miguel Ortiz-Sanjuán ¹, Elvira Vicens Bernabeu ¹, Carmen Nájera Herranz ¹, Inés Cánovas Olmos ¹, Samuel Leal Rodriguez ¹ and José Andrés Román Ivorra ¹, ¹Rheumatology Department. HUP La Fe, Valencia, Comunidad Valenciana, Spain, ²Rheumatology Department. HUP La Fe, v, Comunidad Valenciana, Spain
Background/Purpose: Polyautoimmunity (PAI) is the presence of more than one Autoimmune Disease (AID) in one patient. PAI have been reported in different AIDs as systemic…
Abstract Number: 2151 • 2019 ACR/ARP Annual Meeting
Patient Reported Outcomes and Factors Predicting Clinical Disease Activity in Patients with Immune-Checkpoint Inhibitor Inflammatory Arthritis
Caoilfhionn Connolly¹, Tawnie Braaten ¹, Ami Shah ¹, Clifton Bingham ² and Laura Cappelli ², ¹Johns Hopkins Hospital, Baltimore, MD, ²Johns Hopkins University, Baltimore, MD
Background/Purpose: Immune checkpoint inhibitors (ICIs) enhance anti-tumor immunity by stimulating a patient’s immune system to fight cancer. ICIs have demonstrated unprecedented response rates in a…
Abstract Number: 2152 • 2019 ACR/ARP Annual Meeting
Safety of Immune Checkpoint Inhibitors in Patients Treated for Cancer with Pre-existing Autoimmune Diseases
Aneet Kaur ¹, Umang Swami ¹, Munazza Fatima ¹, Meredith Ginn ¹, Jill Stein ¹, Yubo Gao ¹, Yousef Zakharia ¹ and Namrata Singh², ¹University of Iowa Hospitals and clinics, Iowa city, IA, ²University of Iowa, Iowa City
Background/Purpose: Patients with pre-existing autoimmune diseases (AID) have been traditionally excluded from clinical trials of immune checkpoint inhibitors (ICI), so the data on risk of…
Abstract Number: 2153 • 2019 ACR/ARP Annual Meeting
Ocular Scleral Pathology and Relationship with Autoimmune Diseases: Study of 101 Patients from a Single Universitary Centre
Lara Sanchez-Bilbao¹, Iñigo Gonzalez-Mazon ², Mónica Calderón-Goercke ³, DIANA PRIETO- PENA ², Jose Luis Martín-Varillas ¹, Belén Atienza-Mateo ¹, Rosalia Demetrio ⁴, Miguel A Gonzalez-Gay ¹ and Ricardo Blanco ¹, ¹Rheumatology, Hospital Universitario Marques de Valdecilla, Santander, Spain, ²Rheumatology, Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain, ³Hospital Marqués de Valdecilla, Santander, Cantabria, Spain, ⁴Hospital Universitario Marqués de Valdecilla, Santander, Spain
Background/Purpose: Ocular scleral pathology may be associated with autoimmune diseases. Our aim was to assess a) the epidemiological and clinical features and b) the relationship…
Abstract Number: 2154 • 2019 ACR/ARP Annual Meeting
Role of Insulin Resistance and Inflammation on Resting Energy Expenditure in Patients with Rheumatoid Arthritis
Beatriz Hanaoka¹ and Barbara Gower ², ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham
Background/Purpose: In patients with rheumatoid arthritis(RA), elevated resting energy expenditure(REE) is associated with rheumatoid cachexia and protein catabolism driven by pro-inflammatory cytokines. IR is also…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].